Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. crawled time : 07:00 save search
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-16 (Crawled : 07:00) - biospace.com/
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
fda active
Optic Nerve Disorder Treatment Market to Reach USD 5.3 Billion, Globally, by 2031 at 4.5% CAGR: Allied Market Research
Published: 2023-02-27 (Crawled : 07:00) - prnewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.74%
H: 0.7%
C: -1.59%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 0.64%
H: 0.01%
C: -0.72%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 0.36%
H: 0.97%
C: 0.67%
treatment research market
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis Everest Medicines announced that its licensing partner, Pfizer Inc. has received acceptance from the U.S. Food and Drug Administration for review a New Drug Application for etrasimod for individuals living with moderately-to-severely active ulcerative colitis.
Published: 2022-12-22 (Crawled : 07:00) - biospace.com/
CYDY | $0.148 0.06% 1.5M
|
Manufacturing
|
| O: -4.34%
H: 0.35%
C: -5.13%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda drug active ema application review food living ulcerative colitis
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
Published: 2022-12-01 (Crawled : 07:00) - globenewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.36%
H: 1.68%
C: 1.53%
valneva candidate disease report antibody children vaccine
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
Published: 2021-11-17 (Crawled : 07:00) - globenewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
treatment germany cancer trial
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Published: 2021-06-22 (Crawled : 07:00) - prnewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: 0.51%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.7%
H: 0.05%
C: -1.06%
HALO M | $38.02 -0.94% -0.95% 700K
|
Health Technology
|
| O: 0.19%
H: 2.15%
C: 1.89%
collaboration drug license technology drug delivery liver hiv
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
Published: 2021-06-10 (Crawled : 07:00) - globenewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.23%
H: 2.06%
C: 1.95%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.21%
H: 1.07%
C: 0.67%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -0.62%
H: 3.19%
C: -0.08%
covid vaccine
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
Published: 2021-05-11 (Crawled : 07:00) - globenewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.45%
H: 0.98%
C: -0.83%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.47%
H: 0.7%
C: 0.52%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -7.78%
H: 8.52%
C: 6.11%
covid vaccine merge authorized covid-19
Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Published: 2021-05-04 (Crawled : 07:00) - prnewswire.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.43%
H: 0.43%
C: -0.13%
europe prostate cancer cancer hormone approval
Final Results for the year ended 31 December 2020
Published: 2021-04-01 (Crawled : 07:00) - 4dpharmaplc.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.19%
H: 0.41%
C: 0.0%
LGND | News | $78.93 -1.24% -1.25% 180K
|
Health Technology
|
| O: 1.21%
H: 1.62%
C: 0.2%
results
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.